<br />
DERMATOLOGY<br />
EMJ Dermatol. 2019 Suppl 3 • europeanmedical-journal.com<br />
INSIDE<br />
Translating Evidence to Practice:<br />
From Clinical Research to<br />
Real-World Experience<br />
Job number: SAGLB.DUP.18.10.1273<br />
Approved December 2018<br />
Translating Evidence to Practice:<br />
From Clinical Research to Real-World Experience<br />
This symposium took place on 13th September 2018,<br />
as part of the 27th European Academy of Dermatology<br />
and Venereology (EADV) Congress in Paris, France<br />
Chairpeople: Thomas Bieber1<br />
Speakers: Emma Guttman-Yassky,2 Thomas Bieber,1 Diamant Thaçi3<br />
1. Department of Dermatology and Allergy, Christine Kühne-Center for Allergy<br />
Research and Education, University Medical Center of Bonn, Bonn, Germany<br />
2. Icahn School of Medicine at Mount Sinai, New York City, New York, USA<br />
3. University of Lübeck, Lübeck, German<a title="EMJ Dermatol. 2019 Suppl 3 page 1" href="http://viewer.zmags.com/publication/3af6db6c?page=1"> DERMATOLOGY EMJ Dermatol. 2019 Suppl 3 • european</a>
<a title="EMJ Dermatol. 2019 Suppl 3 page 2" href="http://viewer.zmags.com/publication/3af6db6c?page=2"> Translating Evidence to Practice:</a>
<a title="EMJ Dermatol. 2019 Suppl 3 page 3" href="http://viewer.zmags.com/publication/3af6db6c?page=3"> Prof Bieber explained the need to evaluate </a>
<a title="EMJ Dermatol. 2019 Suppl 3 page 4" href="http://viewer.zmags.com/publication/3af6db6c?page=4"> disease. The role of systemic inflammation is well</a>
<a title="EMJ Dermatol. 2019 Suppl 3 page 5" href="http://viewer.zmags.com/publication/3af6db6c?page=5"> A 4-week study of weekly injections o</a>
<a title="EMJ Dermatol. 2019 Suppl 3 page 6" href="http://viewer.zmags.com/publication/3af6db6c?page=6"> 3–7=mild, 8–16=moderate, 17–24=severe, and </a>
<a title="EMJ Dermatol. 2019 Suppl 3 page 7" href="http://viewer.zmags.com/publication/3af6db6c?page=7"> polypharmacy.52 The majority of moderate-to- seve</a>
<a title="EMJ Dermatol. 2019 Suppl 3 page 8" href="http://viewer.zmags.com/publication/3af6db6c?page=8"> Challenges of Long-Term Therapy in Moderate</a>
<a title="EMJ Dermatol. 2019 Suppl 3 page 9" href="http://viewer.zmags.com/publication/3af6db6c?page=9"> treated on a once-a-week basis for up to 3 years,</a>
<a title="EMJ Dermatol. 2019 Suppl 3 page 10" href="http://viewer.zmags.com/publication/3af6db6c?page=10"> After 4 weeks of dupilumab, his skin lesions show</a>
<a title="EMJ Dermatol. 2019 Suppl 3 page 11" href="http://viewer.zmags.com/publication/3af6db6c?page=11"> 16. Howell MD et al. Th2 cytokines act </a>
<a title="EMJ Dermatol. 2019 Suppl 3 page 12" href="http://viewer.zmags.com/publication/3af6db6c?page=12"> European Task Force on Atopic Dermatitis; Europea</a>